Digital Health Investment

your vision
to life

Fuel your digital health ambition with strategic funding

Bold healthtech ideas can change the way disease is managed and treated. As Debiopharm’s strategic corporate fund, we invest in digital health, smart data & innovative tech start-ups. Are you an entrepreneur seeking funding for your digital health start-up?

Let us help you take your ambition to the next level.

Company stage
Late pilot or early commercial
Investment round
Series A and B
Our typical initial investment
$3M - 5M
Discover our investment criteria
Investment portfolio

Current and past Investments


Discover the success stories of entrepreneurs like you

Surviving & thriving in a tough market

What can start-up executives do to ensure they get to the other side of the market downturn? We interviewed a number of experienced investors and entrepreneurs who have been through good and bad times

Read the white paper
From Series A to scaling up

Useful insights from start-up founders, CEOs and experienced investors. Learn about the main success factors of this exciting stage of entrepreneurship

Read the report
Latest portfolio press releases
March 29, 2023

Genialis Raises $13M to Build Clinical Biomarkers that Predict Patient Response

Read more
March 9, 2023

Iktos announces closing of € 15.5M series A round co-led by M Ventures and Debiopharm

Read more
See all
Latest portfolio news
June 5, 2023

Nucleai and Adlai Nortye Partner to Identify and Validate Novel Spatial Biomarkers Across Adlai Clinical Trials

Read more
May 31, 2023

Genialis release Expressions version 3.0 to accelerate translational and clinical biomarker discovery

Read more
Latest news

Our mission

Support companies like yours

Your technologies and business models aim to make drug development and treatment more patient centric, accessible and affordable?

We seek startups like yours that improve the cancer patient journey and re-imagine how clinical trials are conducted.

We are also interested in digital health companies focused on bacterial infections.

In the area of disruptive therapeutic platforms, we invest in solutions focused on gene and cell therapies.

You will have access to our expertise situated at the crossroads of technological solutions and pharmaceutical know-how which include: Drug development, Regulatory processes, Reimbursement and market access, Management of health-tech companies.

With the aim to

  • Increase the pace of your scale-up process with strategic guidance and piloting,
  • Provide long-term, evergreen funding with multiple financing rounds,
  • Work along with your team to achieve a positive return on investment for all stakeholders,
  • Drive our portfolio investments towards successful exits.

Our track record for your entrepreneurial success

  • Lead investor in 19 out of 25 last investment rounds
  • USD 120 million invested since 2008
  • Portfolio companies have achieved 10 FDA clearances, 13 CE marks & 2 IPOs and 4 trade exits
  • Cumulative equity raised accross companies: over USD 500 million

Leadership team

Discover the people who guide and bring long-term vision to the digital health investments at Debiopharm

Meet our team
Are you an entrepreneur seeking funding

Discover how we can help you take your ambition to the next level

Discover how we can help you